Mediwound Ltd (MDWD) - Total Assets
Based on the latest financial reports, Mediwound Ltd (MDWD) holds total assets worth $94.42 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Mediwound Ltd - Total Assets Trend (2012–2024)
This chart illustrates how Mediwound Ltd's total assets have evolved over time, based on quarterly financial data. Also see Mediwound Ltd (MDWD) market capitalisation for the company's overall valuation and market capitalisation.
Mediwound Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Mediwound Ltd's total assets of $94.42 Million consist of 71.0% current assets and 29.0% non-current assets. Review Mediwound Ltd balance sheet liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 12.5% |
| Accounts Receivable | $5.85 Million | 8.0% |
| Inventory | $2.69 Million | 3.7% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $99.00K | 0.1% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how Mediwound Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See latest Mediwound Ltd stock price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Mediwound Ltd's current assets represent 71.0% of total assets in 2024, an increase from 12.8% in 2012.
- Cash Position: Cash and equivalents constituted 12.5% of total assets in 2024, up from 1.3% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 20.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 8.0% of total assets.
Mediwound Ltd Competitors by Total Assets
Key competitors of Mediwound Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $2.19 Billion |
|
Genscript Biotech Corporation
F:G51
|
Germany | €4.85 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
89bio Inc
NASDAQ:ETNB
|
USA | $603.49 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.78 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
Mediwound Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.65 | 2.11 | 3.17 |
| Quick Ratio | 2.48 | 1.99 | 3.00 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $43.28 Million | $28.31 Million | $17.93 Million |
Mediwound Ltd - Advanced Valuation Insights
This section examines the relationship between Mediwound Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.55 |
| Latest Market Cap to Assets Ratio | 2.34 |
| Asset Growth Rate (YoY) | 10.6% |
| Total Assets | $73.50 Million |
| Market Capitalization | $171.99 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Mediwound Ltd's assets at a significant premium (2.34x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Mediwound Ltd's assets grew by 10.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Mediwound Ltd (2012–2024)
The table below shows the annual total assets of Mediwound Ltd from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $73.50 Million | +10.59% |
| 2023-12-31 | $66.46 Million | +32.88% |
| 2022-12-31 | $50.02 Million | +153.32% |
| 2021-12-31 | $19.74 Million | -36.45% |
| 2020-12-31 | $31.07 Million | -23.45% |
| 2019-12-31 | $40.59 Million | +15.06% |
| 2018-12-31 | $35.28 Million | -20.07% |
| 2017-12-31 | $44.13 Million | +23.41% |
| 2016-12-31 | $35.76 Million | -31.91% |
| 2015-12-31 | $52.52 Million | -26.15% |
| 2014-12-31 | $71.12 Million | +379.70% |
| 2013-12-31 | $14.83 Million | -41.72% |
| 2012-12-31 | $25.44 Million | -- |
About Mediwound Ltd
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in patients with deep partial- and full-thickness thermal burns to burn centers an… Read more